Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

ICON3: A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
ICON3: A Phase 3 Study of Eltrombopag vs. Standard Therapy for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
Sponsor:Baylor College of Medicine
Enrolling:Male and Female Patients
Study Length:1 Years
Clinic Visits:14
Age Range:Between 1 and 18 years old
IRB Number:AAAS3726
U.S. Government ID:NCT03939637
Contact: Cindy Neunert, MD: 212-305-9770 / cn2401@cumc.columbia.edu
Additional Study Information:

The purpose of this study is investigate the safety and effectiveness of eltrombopag (investigational drug) in treating children and adolescents with newly-diagnosed immune thrombocytopenia (ITP), which is a rare blood disorder.

Do You Qualify?
Is your child between the ages of 1 and 18?YesNo
Has your child been recently diagnosed with ITP?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Cindy Neunert, MD
Email: cn2401@cumc.columbia.edu
Phone: 212-305-9770